Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 13Phase 1/2 7Phase 3 3Phase EARLY_PHASE1 2Phase NA 1Phase 2/3 1

Status

Terminated 2Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Brain Neoplasms 2Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Topotecan × Clear all
NCT03927274 2023-05-25

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Terminated
3 enrolled
CNS

Brain Neoplasms, Glioma

NCT02500459 2019-03-01

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
9 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡